|
Thursday 14th September 2023 |
Text too small? |
Cannasouth Limited (NZX: CBD ) has exported to Australia its first commercial shipment of its high-purity cannabidiol (CBD) isolate, a cannabis-based, active pharmaceutical ingredient (API). This is a first for Aotearoa New Zealand’s medicinal cannabis industry.
This CBD isolate was manufactured in New Zealand to PIC/s Good Manufacturing Practice (GMP) standards and verified by the Medicinal Cannabis Agency. This first shipment is the forerunner of greater volumes of API exports for the local industry, signalling the demand for high-quality, GMP certified cannabis-based APIs on the international stage.
This signals the next growth phase for Cannasouth and the medicinal cannabis industry.
-ENDS-
No comments yet
Devon Funds Morning Note - 11 March 2026
BGP - Full Year Results to 25 January 2026
BRM - Scheme of Arrangement Update - NZ Commerce Commission
The oil shock
Air New Zealand suspends FY2026 guidance
March 10th Morning Report
FSF - Mainland Group sale unconditional
TRU - Study Confirms Superiority of TruScreen+hr-HPV co-testing
March 9th Morning Report
March 6th Morning Report